Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Proposes Increased Base Rates For Drugs In 2002 Medicare OPPS

Executive Summary

The Centers for Medicare & Medicaid Services should raise the base rates for drugs in the Medicare hospital outpatient prospective payment system to offset a 68.9% pro-rata reduction in "pass-through" payments, the Biotechnology Industry Organization contends
Advertisement

Related Content

Zevalin Medicare Reimbursement: Idec Predicts Smooth Transition Into 2003
Zevalin Medicare Reimbursement: Idec Predicts Smooth Transition Into 2003
CMS Should Conduct Annual Survey To Determine OPPS Reimbursement – BIO
CMS Should Conduct Annual Survey To Determine OPPS Reimbursement – BIO
Idec Zevalin Approval Delayed By Manufacturing Issues At Catalytica
Idec Zevalin Approval Delayed By Manufacturing Issues At Catalytica
Medicare Outpatient Payment Rate Should Be AWP-25%, Rep. Thomas Says
Medicare Outpatient Payment Rate Should Be AWP-25%, Rep. Thomas Says
Advertisement
UsernamePublicRestriction

Register

PS038919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel